Intellicule, a software company whose solutions determine the 3D structures of biomolecules imaged with cryogenic-electron microscopy (cryo-EM), has received a $217,941 Small Business Innovation ...

March Bio is continuing enrollment in the Phase 2 trial, with the Independent Data Monitoring Committee's approval to advance to Simon Stage 2 of the Phase 2 trial. The Company anticipates presenting ...

Oligomerix Awarded $0.5 M phase I NIH SBIR Fast-Track Grant to Conduct Safety Studies that will Support Clinical Studies of OLX-07010 for Alzheimer’s Patients -- Company gains NIH Fast-Track award ...

NIH funding supports a clinical trial of Storii’s telephone-based memoir service that reduces isolation, improves mental health, and connects rural older adults With just a telephone call, we’re ...

What is the effectiveness of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Institutes of Health (NIH)? An ad hoc committee will ...

Oligomerix, Inc., a privately held clinical stage company pioneering the development of oral, small molecule therapeutics targeting Alzheimer’s (AD) and rare neurodegenerative diseases, announced an ...

Continued organic quarter over quarter revenue growth despite expected summer seasonalityEarnings per share for Q3, 2025: ($0 ...

Biotech veteran with over 25 years of business development, strategy and operational experience joins March Bio’s management teamHOUSTON, Dec.